Items Tagged ‘Alecensa’

December 24th, 2015

Alecensa ™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer


The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa ™ (Alectinib) is indicated for advanced, metastatic, ALK-positive NSCLC in patients unresponsive to or intolerant of another ALK inhibitor, Xalkori ™ (crizotinib). The investigative agent, Alecensa, produces high anti-cancer responses […]

View full entry

Tags: Alecensa, alectinib, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc